Trial · NCT06581055
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant treatment patterns: Type of treatment received | Up to 24 months | |
| Primary | Participant treatment patterns: Duration of treatment received | Up to 24 months | |
| Primary | Participant treatment patterns: Dosage of treatment received | Up to 24 months | |
| Primary | Participant treatment patterns: Dosing route of treatment administration | Up to 24 months | |
| Primary | Participant treatment patterns: Reason for treatment administration | Up to 24 months | |
| Primary | Participant treatment patterns: Time to next line of therapy (LoT) | Up to 24 months | |
| Primary | Participant treatment patterns: Reason for treatment discontinuation | Up to 24 months | |
| Primary | Participant treatment patterns: Type of concomitant medications received | Up to 24 months | |
| Primary | Participant treatment patterns: Start and end dates of concomitant medications received | Up to 24 months | |
| Secondary | Participant clinical outcomes: Number of units of red blood cell transfusions received | Up to 24 months | |
| Secondary | Participant clinical outcomes: Red blood cell transfusion burden (RBC-TB) category | Up to 24 months | Category 1: Transfusion dependent (at least 4 units of red blood cell (RBC) with 8 weeks for hemoglobin (Hb) \<9g/dL) Category 2: Transfusion independence (\<4 units of RBC with 8 weeks for Hb \<9 g/dL) |
| Secondary | Participant clinical outcomes: Red blood cell transfusion burden (RBC-TB) category per International Working Group (IWG) 2018 | Up to 24 months | IWG 2028 criteria: 1. Non-transfused (0 Red Blood Cells \[RBC\] in 16 weeks) 2. Low-transfusion burden (3-7 RBCs in 16 weeks in at least 2 transfusion episodes, maximum 3 in 8 weeks) 3. High-transfusion burden (≥8 RBCs in 16 week, ≥4 in 8 weeks) |
| Secondary | Participant clinical outcomes: Blood test results | Up to 24 months | |
| Secondary | Participant clinical outcomes: Number of participants that progressed to acute myeloid leukemia (AML) status | Up to 24 months | |
| Secondary | Number of participants that progressed to high-risk myelodysplastic syndromes (MDS) | Up to 24 months | |
| Secondary | Participant clinical outcomes: Participant survival status | Up to 24 months | |
| Secondary | Participant clinical outcomes: Date and primary cause of death | Up to 24 months | |
| Secondary | Participant clinical characteristics | Up to 24 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06581055/registered